Global DiGeorge Syndrome Drug Market Highlights 2020-2029
The global DiGeorge syndrome drug market is expected to grow at a substantial CAGR during the forecast period of 2021-2029. The market growth is driven by the growing patient pool of the disease and the need for treatment for the wide range of symptoms caused by this genetic disorder. The symptoms of this disorder include congenital heart disease, cleft palate, learning and development delay, and mental disorders including autism spectrum disorder (ASD), anxiety disorder, and psychotic disorders, such as, schizophrenia among others. These symptoms may vary from person to person, which induces the need for a different and specific treatment approach for every individual. This, in turn, is estimated to boost the market growth by the end of 2029. Moreover, the cause of deletion of chromosome 22 is still unknown, creating vast scope for research activities in this direction, which is estimated to generate immense opportunity for the market growth throughout the forecast period.
The global DiGeorge syndrome drug market is segmented based on route of administration into oral and injectable, out of which, the oral administration segment is anticipated to garner major share during the forecast period in the market considering the ease and convenience of receiving the treatment. Based on end-user, the market is segmented into hospitals, homecare, speciality clinics and others, out of which speciality clinics are anticipated to hold a significant market share by the end of 2029 as these clinics are mostly preferred by patients owing to the availability of focused and specified treatment for the DiGeorge syndrome. CLICK TO DOWNLOAD SAMPLE REPORT
However, the treatment can be very expensive and long-stretched, causing financial and mental stress to the patients and their family. This can act as a restraint for the growth of the DiGeorge syndrome drug market. Additionally, with the expiry of patents of drugs from many companies, the chance of generic drugs being introduced in the market is high, which is further estimated, to hamper market growth over the forecast period.
Global DiGeorge Syndrome Drug Market Regional Synopsis
On the basis of regional analysis, the global DiGeorge syndrome drug market is segmented into five major regions including North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa region.
The market in the North America is anticipated to garner significant revenue during the forecast period on the back of rising prevalence of the disorder. DiGeorge syndrome occurs in 1 in every 3000 to 6000 births in the U.S. and its proximity is equal between males and females. Additionally, the market is projected to witness significant growth owing to the growing medical advancements combined with efficient healthcare sector in the region. According to the World Health Organization (WHO), as of 2018, 16.416 % of the GDP was spent on the healthcare sector in North America. Moreover, increasing investments by the government on research and development activities for the development of newer treatment methods and more effective drugs are additional factors estimated to contribute towards the market growth in the forecast period. The market in the Asia Pacific is anticipated to witness notable growth accounting to the increasing population and prevalence of DiGeorge syndrome in the region. Gradual, yet constant development in the public healthcare system in the APAC region also tends to positively affect the market growth.
The global DiGeorge syndrome drug market is further classified on the basis of region as follows:
- North America (U.S. & Canada) Market size, Y-O-Y growth & Opportunity Analysis
- Latin America (Brazil, Mexico, Argentina, Rest of Latin America) Market size, Y-O-Y growth & Opportunity Analysis
- Europe (U.K., Germany, France, Italy, Spain, Hungary, Belgium, Netherlands & Luxembourg, NORDIC, Poland, Turkey, Russia, Rest of Europe) Market size, Y-O-Y growth & Opportunity Analysis
- Asia-Pacific (China, India, Japan, South Korea, Indonesia, Malaysia, Australia, New Zealand, Rest of Asia-Pacific) Market size, Y-O-Y growth & Opportunity Analysis.
- Middle East and Africa (Israel, GCC (Saudi Arabia, UAE, Bahrain, Kuwait, Qatar, Oman), North Africa, South Africa, Rest of Middle East and Africa) Market size, Y-O-Y growth & Opportunity Analysis
Market Segmentation
Our in-depth analysis of the global DiGeorge syndrome drug market includes the following segments:
By Route of administration
- Oral
- Injectable
By Therapy Type
- Hormone Replacement Therapy
- Regenerative Medicine Advanced Therapy
By End-Users
- Specialty Clinics
- Homecare
- Hospitals
- Others
Growth Drivers
- Rising Global Prevalence of the DiGeorge Syndrome to Drive the Market Growth
- Increasing R&D Activities for the Development of Better Drugs and Treatment Methods to boost the Market Growth
Restraints
- High Cost of the DiGeorge Syndrome Drugs to Hamper Market Growth
- Increased Circulation of Generic Drugs in the Market and Lack of Awareness Regarding the Disease likely to Challenge the Market Growth
Top Featured Companies Dominating the Market
There is no known cure for DiGeorge Syndrome, but treatment is given for the symptoms, which can be different for different patients. The treatment approach can range from cleft palate surgeries, drugs for mental disorders to behavioural and speech therapy. The major market players manufacturing the various kind of drugs needed to treat the symptoms include F. Hoffmann-La Roche Ltd, Pfizer Inc., Cerecor, Inc., Bausch Health Companies Inc., Natera, Inc, Boehringer Ingelheim International GmbH, AbbVie Inc., Amgen Inc., Novartis AG and Progenity, Inc.
